What starts as a minor inconvenience can snowball into chronic sinusitis, recurrent infections, and even more serious ENT ...

GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...

Adults with chronic rhinosinusitis with nasal polyps can experience persistent nasal obstruction that disrupts restorative sleep. In a systematic review of postoperative data, investigators evaluated ...

Department of Otorhinolaryngology, Centre Hospitalo-Universitaire de Kamenge (CHUK), University of Burundi, Bujumbura, Burundi. Nasal polyposis represents a significant clinical and public health ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the ...

Endoscopic sinus surgery for chronic rhinosinusitis (CRS) provides significantly better disease-specific quality of life at 6 months than long-term, low-dose treatment with the macrolide antibiotic ...

A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive ...

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...